EC Green Lights Bimzelx for HS
The European Commission (EC) has granted marketing authorization for bimekizumab (Bimzelx, UCB) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic therapy. The approval follows a positive opinion issued in March 2024 by the Committee for Medicinal Products for Human Use of the European […]